Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
Study First Submitted
Endpoints
Primary
Proportion of Participants With HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 24, as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Timeframe: Week 24
Secondary (11)
Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 using the US FDA-defined snapshot algorithm
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the US FDA-Defined Snapshot Algorithm
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the US FDA-Defined Snapshot Algorithm
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Change From Baseline in CD4 Cell Count at Week 48
Show 6 moreShow less
Percentage of Participants Experiencing Treatment-Emergent Grade 3 or 4 Adverse Events (AEs)
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse events (SAEs)
Percentage of Participants Experiencing Treatment-Emergent AEs Leading to Discontinuation of Study Drug Through Week 48
Change From Baseline in Patient-Reported Experience and Satisfaction Score, as Assessed by the Questionnaire to Understand the Experience and Satisfaction in a Study in HIV-Treatment (QUEST-HIV-T) at Week 24
Change From Baseline in Patient-Reported Experience and Satisfaction Score, as Assessed by the Questionnaire to Understand the Experience and Satisfaction in a Study in HIV-Treatment (QUEST-HIV-T) at Week 48
Proportion of Participants Reporting a Preference for BIC/LEN FDC Compared with Previous SBR, as Assessed by the HIV-Treatment Preference Questionnaire (HIV-TPQ) at Week 48
Arms and interventions
Immediate Switch Arm: BIC/LEN FDCExperimental
Participants will switch to BIC/LEN (75 mg/50mg) FDC tablets once daily starting on Day 1. Participants will receive a 2-day oral loading dose regimen of LEN 600 mg on Days 1 and 2, in addition to the once-daily doses of BIC/LEN FDC starting on Day 1, up to Week 48.
Participants will remain on their existing SBR antiretroviral therapy (ART) regimen from Day 1 through Week 24.
At Week 24, they will switch to BIC/LEN (75 mg/50 mg) FDC tablets once daily. At the time of BIC/LEN FDC initiation, participants will receive a 2-day oral loading dose regimen of LEN 600 mg on Day 1 and 2, in addition to the once-daily doses of BIC/LEN FDC starting at the time of switch, up to Week 48.